Abstract
Rivastigmine is indirectly acting parasympathomimetic drug that was developed by the pharmaceutical company Novartis. In routine clinical practice came in 1997, as a substance intended for the treatment of dementia of the Alzheimer type.
Since 2006 is also indicated for the treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.